← Back to Clinical Trials
Recruiting NCT06400173

NCT06400173 Validation Of The Flemish Montreal Cognitive Assessment (MoCA) For Persons With Hearing Impairment

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06400173
Status Recruiting
Phase
Sponsor University Ghent
Condition Dementia
Study Type OBSERVATIONAL
Enrollment 450 participants
Start Date 2023-09-01
Primary Completion 2025-12-31

Trial Parameters

Condition Dementia
Sponsor University Ghent
Study Type OBSERVATIONAL
Phase N/A
Enrollment 450
Sex ALL
Min Age 45 Years
Max Age 80 Years
Start Date 2023-09-01
Completion 2025-12-31
Interventions
Cognitive screeningAudiological Assessment

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The Montreal Cognitive Assessment (MoCA) is a screening test for detecting cognitive impairment that assesses several cognitive domains (attention and concentration, arithmetic and orientation, memory, etc.). The instructions as well as some test items of the MoCA are presented auditory (spoken). Consequently, performance on the MoCA may be co-dependent on hearing. Therefore, to rule out the possible negative influence of hearing loss on performance on the MoCA, a MoCA for individuals with hearing loss was recently developed. More specifically, the original MoCA was modified by providing the instructions audiovisually (spoken with visual support) as well as by replacing hearing-dependent items. Since replacing items may affect sensitivity and specificity, the MoCA for persons with hearing loss should be revalidated.

Eligibility Criteria

Inclusion Criteria: * Individuals aged 60 years or older * Individuals with normal vision (with lenses or glasses if needed) * Individuals with age-related hearing loss * Dutch-speaking individuals * Individuals capable of giving consent to participate in the study themselves * Individuals still residing in their own homes * Individuals with an official diagnosis of dementia (Alzheimer's, vascular, or mixed) or mild cognitive impairment. This inclusion criterion applies only to the group with cognitive impairment. Exclusion Criteria: For individuals without cognitive impairment, the following exclusion criteria apply: * (History of) neurological problems (brain tumor, epilepsy, history of stroke, etc.) * Use of influencing medication (e.g., Ritalin and antidepressants)

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology